NCT01325402View on ClinicalTrials.gov

An Open Positron Emission Tomography Study to Assess the Effects of Varying Mass of AZD4694 on Radioligand Binding Parameters in Healthy Volunteers and Patients With Alzheimer's Disease

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

August 31, 2011

Primary Completion Date

November 30, 2012

Study Completion Date

November 30, 2012

Conditions
Maximum Diagnostic Mass of [18Fluor]AZD4694
Interventions
OTHER

[18Fluor]AZD4694

Low mass dose below 5ug. High mass dose around 40 and 50 ug.

OTHER

[18Fluor]AZD4694

Low mass dose below 5ug. High mass dose around 20 ug.

OTHER

[18Fluor]AZD4694

Low mass dose below 5ug. High mass dose will be the Maximum Detective Mass established in the previous panels.

Trial Locations (2)

Unknown

Research Site, Stockholm

Research Site, Uppsala

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY